[Comparison of pingyangmycin fibrin glue composite and pingyangmycin dexamethasone composite in the treatment of pharyngolaryngeal venous malformation].

Objective: To analyze and compare the efficacy and safety of pingyangmycin fibrin glue composite (PFG) and pingyangmycin dexamethasone composite (PD) in the treatment of pharyngolaryngeal venous malformation (VM). Methods: The clinical data of 98 patients with pharyngolaryngeal VM who underwent sclerotherapy with pingyangmycin composite in the First Affiliated Hospital of Sun Yat-sen University from June 2013 to November 2022 were retrospectively analyzed. According to their treatment, patients were divided into PFG group (n=34) and PD group (n=64), among those patients there were 54 males and 44 females, aged 1-77(37.06±18.86)years. The lesion size, total treatment times and adverse events were recorded before and after treatment. And the efficacy was divided into three grades: recovery, effective and invalid. According to the length of VM, all patients were divided into three subgroups, to compare the differences in efficacy and treatment times between each two groups.And finally the adverse events and their treatments were analyzed. SPSS 25.0 software was used for statistical analysis. Results: The efficacy of PFG group was 94.11%(32/34), the recovery rate was 85.29%(29/34).And the efficacy of PD group was 93.75%(60/64), the recovery rate was 64.06%(41/64). No serious adverse eventst occurred in subgroup comparison, there was no statistical difference between the two groups in efficacy and the times of treatments when the length was≤3 cm (Zefficacy=1.04, ttreatment times=2.18, P>0.05); when the length was 3-5 cm, there was no significant efficacy difference between the two groups(Zefficacy=1.17, P>0.05), but the treatment times of PFG were less (ttreatment times=4.87, P<0.01); when the length≥5 cm, efficacy of PFG was significantly better than PD (Zefficacy=2.94, P<0.01), and had fewer treatments times (ttreatment times=2.16, P<0.01). There were no serious adverse events in either group during treatment and follow-up. Conclusion: Both PFG and PD are safe and effective composite sclerotherapy agent for the treatment of laryngeal VM, but PFG has a higher cure rate and fewer treatment times for massive lesions.

[Detection and genotyping of astroviruses by RT-PCR and sequencing].

Three primer pairs, AV244Mon and 82b, AV-15Gr and AV-12Gr, and Beg and End, were used for the detection of standard astroviruses (serotype 1 to serotype 7) in cell culture and astroviruses isolated from 89 diarrheal stool specimens negative for pathogenic bacteria, rotavirus and adenovirus by the reverse transcription-polymerase chain reaction (RT-PCR). All the standard strains and two isolates were detected by primer pairs AV244Mon and 82b, and AV-15Gr and AV-12Gr. All serotypes except serotype 4 were detected by the primer pair Beg and End. The molecular sizes of the RT-PCR products obtained by Beg and End were almost the same among the different serotypes except serotype 6. Sequence analyses of the nucleic acid in the regions between the primer pairs AV244Mon and 82b, and between Beg and End from PCR products of the standard strains and from the isolates of the two stool specimens revealed that each serotype had a unique sequence. These results indicate that the RT-PCR is useful for detecting and genotyping astroviruses.

[Study on the genetic variations of the major neutralization antigen VP7 of group A rotavirus type G1 in China].

OBJECTIVE: To study the genetic variations of the major neutralization antigen VP7 of group A rotavirus, type G1 in China. METHODS: Twenty-three isolates derived from seven cities (Beijing, Shenyang, Xinxiang, Shanghai, Shenzhen, Guangzhou and Chongqing) during the period of 1988-1998 were analyzed for the VP7 cDNA sequences. RESULTS: An obvious homology was observed in amino acid sequences of VP7 in the 23 isolates. Compared with the standard strain Wa, the variations were found at the position of aa 41, 49, 57, 65, 68, 74, 94, 97, 147, 170, 217, 218, 268, 281 and 291, respectively, and all of these were located in the variable region(VR)3,4,5,7,8 as well as in the C-terminal of the peptide. There seemed to be no remarkable divergence among the samples collected from different cities and all of them shared the same genetic lineage with the strain Jpn-417, though there might be one or two amino acid substitutions as time passed. When detected simultaneously with ELISA using G1 serotype-specific monoclonal antibody, the location of amino acid 91 was found presumably related to the neutralization epitope in VP7 of the type G1. Variations at some position may be resulted in the change of electropherotype. CONCLUSIONS: The results indicated that the recent isolates with representative genetic and antigenic features should be used to develop effective vaccines, and the antigenic variations should be monitored periodically.